|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2000-11-22
|
|
pubmed:abstractText |
Programmed cell death is an important determinant of the response to chemotherapy. Among the factors controlling this process, a significant role is played by bcl-2, bax and p53. The in vitro chemosensitivity of the 177 breast carcinomas was assessed by the histoculture drug response assay (HDRA) using mitomycin C (MMC), 5-fluorouracil (5-Fu), adriamycin (ADM), cisplatin (CDDP), and cyclophosphamide (CPA). The susceptibility of Bcl-2-negative tumors to all the drugs killing was significantly higher than that of Bcl-2-positive tumors. No relationship between Bax or p53 immunoreactivity and sensitivity for any of anticancer drugs studied was demonstrated. Immunohistochemical results regarding Bcl-2 are promising in the evaluation of the sensitivity of cancer cells to a series of anticancer drugs and might be therapeutically useful as an indicator of response to adjuvant chemotherapy for breast cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0167-6806
|
|
pubmed:author |
pubmed-author:KakudoKK,
pubmed-author:KokawaYY,
pubmed-author:MoraAA,
pubmed-author:NakamuraMM,
pubmed-author:NakamuraYY,
pubmed-author:SakuraiTT,
pubmed-author:ShawEE,
pubmed-author:SuzumaTT,
pubmed-author:TamakiTT,
pubmed-author:TaniYY,
pubmed-author:UmemuraTT,
pubmed-author:UtsunomiyaHH,
pubmed-author:YangQ FQF,
pubmed-author:YoshimuraGG
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
61
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
211-6
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10965997-Antineoplastic Agents,
pubmed-meshheading:10965997-Breast Neoplasms,
pubmed-meshheading:10965997-Carcinoma, Ductal, Breast,
pubmed-meshheading:10965997-Carcinoma, Lobular,
pubmed-meshheading:10965997-Drug Resistance, Neoplasm,
pubmed-meshheading:10965997-Female,
pubmed-meshheading:10965997-Humans,
pubmed-meshheading:10965997-Immunoblotting,
pubmed-meshheading:10965997-Immunoenzyme Techniques,
pubmed-meshheading:10965997-Proto-Oncogene Proteins,
pubmed-meshheading:10965997-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:10965997-Statistics, Nonparametric,
pubmed-meshheading:10965997-Tumor Suppressor Protein p53,
pubmed-meshheading:10965997-bcl-2-Associated X Protein
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma.
|
|
pubmed:affiliation |
Department of Surgery, Affiliated Kihoku Hospital, Wakayama Medical College, Wakayama City, Japan. yang-qf@mail.wakayama-med.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
